Trade Fresenius Medical Care AG & Co KGaA - FME CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.13 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.022085% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000137% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | Germany | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Fresenius Medical Care AG ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 34.83 |
Open* | 34.98 |
1-Year Change* | -4.24% |
Day's Range* | 34.98 - 35.51 |
52 wk Range | 30.16-49.62 |
Average Volume (10 days) | 394.97K |
Average Volume (3 months) | 9.53M |
Market Cap | 10.42B |
P/E Ratio | 23.15 |
Shares Outstanding | 293.41M |
Revenue | 19.46B |
EPS | 1.53 |
Dividend (Yield %) | 3.15493 |
Beta | 0.92 |
Next Earnings Date | Feb 20, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 18, 2024 | 34.83 | 0.04 | 0.11% | 34.79 | 35.16 | 34.67 |
Mar 15, 2024 | 34.64 | -1.28 | -3.56% | 35.92 | 36.18 | 34.59 |
Mar 14, 2024 | 36.23 | -0.40 | -1.09% | 36.63 | 36.88 | 36.02 |
Mar 13, 2024 | 36.69 | -0.12 | -0.33% | 36.81 | 36.99 | 36.53 |
Mar 12, 2024 | 36.78 | 0.02 | 0.05% | 36.76 | 36.95 | 36.27 |
Mar 11, 2024 | 36.99 | 0.25 | 0.68% | 36.74 | 37.31 | 36.63 |
Mar 8, 2024 | 36.59 | -0.90 | -2.40% | 37.49 | 37.74 | 36.59 |
Mar 7, 2024 | 37.15 | 0.63 | 1.73% | 36.52 | 37.84 | 36.49 |
Mar 6, 2024 | 36.93 | -1.16 | -3.05% | 38.09 | 38.25 | 36.60 |
Mar 5, 2024 | 38.23 | 4.27 | 12.57% | 33.96 | 38.66 | 33.73 |
Mar 4, 2024 | 34.42 | -1.03 | -2.91% | 35.45 | 35.53 | 34.08 |
Mar 1, 2024 | 35.52 | 0.13 | 0.37% | 35.39 | 35.74 | 35.12 |
Feb 29, 2024 | 34.74 | -0.84 | -2.36% | 35.58 | 35.82 | 34.74 |
Feb 28, 2024 | 35.69 | -0.28 | -0.78% | 35.97 | 36.64 | 35.57 |
Feb 27, 2024 | 36.12 | -0.04 | -0.11% | 36.16 | 36.38 | 35.58 |
Feb 26, 2024 | 36.34 | 0.89 | 2.51% | 35.45 | 36.80 | 34.86 |
Feb 23, 2024 | 35.40 | -0.15 | -0.42% | 35.55 | 35.72 | 34.95 |
Feb 22, 2024 | 35.86 | 0.28 | 0.79% | 35.58 | 36.06 | 35.19 |
Feb 21, 2024 | 35.47 | -1.74 | -4.68% | 37.21 | 37.42 | 35.36 |
Feb 20, 2024 | 37.65 | -3.75 | -9.06% | 41.40 | 41.42 | 36.34 |
Fresenius Medical Care AG & Co KGaA Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, May 7, 2024 | ||
Time (UTC) 05:00 | Country DE
| Event Q1 2024 Fresenius Medical Care AG Earnings Release Q1 2024 Fresenius Medical Care AG Earnings ReleaseForecast -Previous - |
Time (UTC) 10:59 | Country DE
| Event Q1 2024 Fresenius Medical Care AG Earnings Call Q1 2024 Fresenius Medical Care AG Earnings CallForecast -Previous - |
Thursday, May 16, 2024 | ||
Time (UTC) 10:59 | Country DE
| Event Fresenius Medical Care AG Annual Shareholders Meeting Fresenius Medical Care AG Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 19398 | 17618.7 | 17859.1 | 17476.6 | 16546.9 |
Revenue | 19398 | 17618.7 | 17859.1 | 17476.6 | 16546.9 |
Cost of Revenue, Total | 14087.8 | 12541.7 | 12321.6 | 12080.7 | 11392.1 |
Gross Profit | 5310.25 | 5077.03 | 5537.44 | 5395.85 | 5154.74 |
Total Operating Expense | 17886.3 | 15766.4 | 15554.7 | 15207 | 13509.1 |
Selling/General/Admin. Expenses, Total | 3528.86 | 2996.98 | 3102.8 | 2939.13 | 2709.78 |
Research & Development | 218.63 | 214.345 | 188.75 | 164.976 | 133.274 |
Depreciation / Amortization | 9.994 | 6.437 | 5.024 | 3.052 | 0.341 |
Interest Expense (Income) - Net Operating | 29.864 | -26.024 | -115.456 | -73.611 | -65.408 |
Unusual Expense (Income) | 11.147 | 33.005 | 51.92 | 92.744 | -661.043 |
Operating Income | 1511.76 | 1852.29 | 2304.41 | 2269.56 | 3037.8 |
Interest Income (Expense), Net Non-Operating | -292.476 | -280.429 | -368.019 | -429.444 | -301.062 |
Net Income Before Taxes | 1219.28 | 1571.86 | 1936.39 | 1840.11 | 2736.74 |
Net Income After Taxes | 894.325 | 1219.03 | 1435.83 | 1438.5 | 2225.66 |
Minority Interest | -220.92 | -249.72 | -271.455 | -238.881 | -243.733 |
Net Income Before Extra. Items | 673.405 | 969.308 | 1164.38 | 1199.62 | 1981.92 |
Net Income | 673.405 | 969.308 | 1164.38 | 1199.62 | 1981.92 |
Income Available to Common Excl. Extra. Items | 673.405 | 969.308 | 1164.38 | 1199.62 | 1981.92 |
Income Available to Common Incl. Extra. Items | 673.405 | 969.308 | 1164.38 | 1199.62 | 1981.92 |
Diluted Net Income | 673.405 | 969.308 | 1164.38 | 1199.62 | 1981.92 |
Diluted Weighted Average Shares | 293.246 | 292.945 | 294.056 | 302.691 | 307.275 |
Diluted EPS Excluding Extraordinary Items | 2.29638 | 3.30884 | 3.95972 | 3.96318 | 6.45 |
Dividends per Share - Common Stock Primary Issue | 1.12 | 1.35 | 1.34 | 1.2 | 1.17 |
Diluted Normalized EPS | 3.98317 | 3.79414 | 4.71608 | 4.2027 | 4.70044 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 4825.28 | 4704.22 | 4996.8 | 5096.17 | 4756.68 |
Revenue | 4825.28 | 4704.22 | 4996.8 | 5096.17 | 4756.68 |
Cost of Revenue, Total | 3628.06 | 3555.08 | 3649.28 | 3737.58 | 3410.63 |
Gross Profit | 1197.21 | 1149.14 | 1347.52 | 1358.59 | 1346.05 |
Total Operating Expense | 4468.65 | 4443.28 | 4644.87 | 4624.52 | 4416.17 |
Selling/General/Admin. Expenses, Total | 775.235 | 782.154 | 954.297 | 989.607 | 969.489 |
Research & Development | 54.756 | 53.332 | 59.237 | 58.452 | 53.334 |
Depreciation / Amortization | 2.428 | 2.428 | 2.812 | 3.032 | 2.084 |
Interest Expense (Income) - Net Operating | -32.101 | -15.251 | -19.257 | -17.448 | -19.367 |
Operating Income | 356.627 | 260.937 | 351.934 | 471.643 | 340.51 |
Interest Income (Expense), Net Non-Operating | -80.543 | -82.572 | -75.315 | -76.485 | -71.579 |
Net Income Before Taxes | 276.084 | 178.365 | 276.619 | 395.158 | 268.931 |
Net Income After Taxes | 194.946 | 133.853 | 193.582 | 282.932 | 206.005 |
Minority Interest | -54.587 | -47.491 | -54.778 | -52.832 | -58.865 |
Net Income Before Extra. Items | 140.359 | 86.362 | 138.804 | 230.1 | 147.14 |
Net Income | 140.359 | 86.362 | 138.804 | 230.1 | 147.14 |
Income Available to Common Excl. Extra. Items | 140.359 | 86.362 | 138.804 | 230.1 | 147.14 |
Income Available to Common Incl. Extra. Items | 140.359 | 86.362 | 138.804 | 230.1 | 147.14 |
Diluted Net Income | 140.359 | 86.362 | 138.804 | 230.1 | 147.14 |
Diluted Weighted Average Shares | 293.413 | 293.413 | 293.415 | 293.413 | 293.145 |
Diluted EPS Excluding Extraordinary Items | 0.47837 | 0.29434 | 0.47306 | 0.78422 | 0.50194 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 1.12 | 0 | 0 |
Diluted Normalized EPS | 0.52934 | 0.52287 | 1.47121 | 0.42868 | 0.70576 |
Unusual Expense (Income) | -3.819 | 80.353 | -1.503 | -146.699 | |
Other Operating Expenses, Total | 44.085 | -14.811 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 8203.46 | 7967.24 | 7275.31 | 7165.15 | 7846.89 |
Cash and Short Term Investments | 1443.77 | 1618.02 | 1243.23 | 1141.05 | 2265.14 |
Cash | 911.015 | 925.134 | 746.851 | 768.706 | 831.885 |
Cash & Equivalents | 362.772 | 556.521 | 334.688 | 239.017 | 1313.75 |
Short Term Investments | 169.983 | 136.362 | 161.688 | 133.322 | 119.507 |
Total Receivables, Net | 3882.04 | 3769.23 | 3579.29 | 3969.26 | 3765.57 |
Accounts Receivable - Trade, Net | 3574.27 | 3409.06 | 3153.04 | 3421.35 | 3337.71 |
Total Inventory | 2296.21 | 2038.01 | 1895.31 | 1663.28 | 1466.8 |
Prepaid Expenses | 410.334 | 377.907 | 374.081 | 178.474 | 135.729 |
Other Current Assets, Total | 171.093 | 164.07 | 183.398 | 213.086 | 213.646 |
Total Assets | 35754.1 | 34366.6 | 31689 | 32934.7 | 26242.3 |
Property/Plant/Equipment, Total - Net | 8339.81 | 8551.47 | 8186.75 | 8515.4 | 3836.01 |
Property/Plant/Equipment, Total - Gross | 17936.7 | 16654.3 | 14830.4 | 14413.4 | 8507.4 |
Accumulated Depreciation, Total | -9596.91 | -8102.86 | -6643.68 | -5897.98 | -4671.39 |
Goodwill, Net | 15791.2 | 14361.6 | 12958.7 | 14017.3 | 12209.6 |
Intangibles, Net | 1518.68 | 1459.39 | 1381.01 | 1426.33 | 681.331 |
Long Term Investments | 773.724 | 786.905 | 761.113 | 696.872 | 649.78 |
Other Long Term Assets, Total | 1127.27 | 1239.97 | 1126.12 | 1113.74 | 1018.66 |
Total Current Liabilities | 6467.31 | 7257.63 | 6159.64 | 7007.23 | 6268.28 |
Accounts Payable | 813.255 | 736.069 | 731.993 | 716.526 | 641.271 |
Accrued Expenses | 2183.85 | 2225.56 | 2115.75 | 1964.24 | 2056.49 |
Notes Payable/Short Term Debt | 669.013 | 1255.85 | 79.27 | 1171.85 | 1394.19 |
Current Port. of LT Debt/Capital Leases | 1367.89 | 1329.54 | 1617.52 | 2086.16 | 1244.73 |
Other Current Liabilities, Total | 1433.31 | 1710.61 | 1615.11 | 1068.46 | 931.597 |
Total Liabilities | 21764.7 | 21667.8 | 20474 | 20976.8 | 14483.9 |
Total Long Term Debt | 11175.7 | 10734.8 | 10683.2 | 10524.6 | 5045.52 |
Long Term Debt | 7170.73 | 6646.95 | 6800.1 | 6458.32 | 5018.76 |
Capital Lease Obligations | 4004.94 | 4087.8 | 3883.13 | 4066.3 | 26.757 |
Deferred Income Tax | 936.475 | 868.452 | 785.886 | 739.702 | 626.521 |
Minority Interest | 1459.73 | 1280.25 | 1116.23 | 1269.32 | 1143.55 |
Other Liabilities, Total | 1725.47 | 1526.68 | 1728.96 | 1435.95 | 1399.99 |
Total Equity | 13989.5 | 12698.8 | 11215.1 | 11957.9 | 11758.4 |
Common Stock | 293.413 | 293.004 | 292.877 | 304.437 | 307.879 |
Additional Paid-In Capital | 3372.8 | 2891.28 | 2872.63 | 3607.66 | 3873.34 |
Retained Earnings (Accumulated Deficit) | 10711.7 | 10826.1 | 10254.9 | 9454.86 | 8831.93 |
Treasury Stock - Common | 0 | -370.502 | -50.993 | ||
Other Equity, Total | -388.468 | -1311.64 | -2205.34 | -1038.55 | -1203.75 |
Total Liabilities & Shareholders’ Equity | 35754.1 | 34366.6 | 31689 | 32934.7 | 26242.3 |
Total Common Shares Outstanding | 293.413 | 293.004 | 292.877 | 298.329 | 306.879 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 9054.21 | 8347.01 | 8561.71 | 8203.46 | 8512.67 |
Cash and Short Term Investments | 1553.25 | 1361.3 | 1223.89 | 1273.79 | 1113.55 |
Cash & Equivalents | 1553.25 | 1361.3 | 1223.89 | 1273.79 | 1113.55 |
Total Receivables, Net | 3714.23 | 3646.05 | 3995.29 | 3714.34 | 3972.16 |
Accounts Receivable - Trade, Net | 3662.14 | 3558.73 | 3905.92 | 3574.27 | 3815.37 |
Total Inventory | 2303.9 | 2335.44 | 2328.03 | 2296.21 | 2409.68 |
Other Current Assets, Total | 1482.82 | 1004.22 | 1014.51 | 919.112 | 1017.27 |
Total Assets | 35634.7 | 34960.1 | 35500.5 | 35754.1 | 38406.4 |
Property/Plant/Equipment, Total - Net | 7885.47 | 7930.77 | 8081.88 | 8339.81 | 9095.34 |
Goodwill, Net | 15407.3 | 15423.3 | 15478.4 | 15791.2 | 17187.1 |
Intangibles, Net | 1406.61 | 1400.53 | 1416.8 | 1518.68 | 1603.8 |
Long Term Investments | 705.102 | 696.388 | 798.025 | 773.724 | 767.699 |
Other Long Term Assets, Total | 1176.03 | 1162.16 | 1163.7 | 1127.27 | 1239.82 |
Total Current Liabilities | 6619.33 | 6624.18 | 6491.84 | 6467.31 | 6357.39 |
Accounts Payable | 753.12 | 720.307 | 822.336 | 813.255 | 828.09 |
Accrued Expenses | 3579.34 | 3337.51 | 3322.33 | 3355.14 | 3878.43 |
Notes Payable/Short Term Debt | 549.829 | 904.334 | 712.94 | 669.013 | 582.523 |
Current Port. of LT Debt/Capital Leases | 1357.58 | 1353.19 | 1354.96 | 1367.89 | 790.326 |
Other Current Liabilities, Total | 379.453 | 308.84 | 279.268 | 262.015 | 278.022 |
Total Liabilities | 21628.1 | 21431.9 | 21672.6 | 21764.7 | 23355 |
Total Long Term Debt | 11067.1 | 10808.3 | 11197.9 | 11175.7 | 12412.7 |
Long Term Debt | 7264.34 | 6997.11 | 7327.59 | 7170.73 | 8068.49 |
Capital Lease Obligations | 3802.76 | 3811.16 | 3870.32 | 4004.94 | 4344.2 |
Deferred Income Tax | 853.787 | 863.968 | 900.165 | 936.475 | 994.803 |
Minority Interest | 1428.01 | 1401.97 | 1399.03 | 1459.73 | 1683.96 |
Other Liabilities, Total | 1659.91 | 1733.54 | 1683.67 | 1725.47 | 1906.18 |
Total Equity | 14006.6 | 13528.2 | 13827.9 | 13989.5 | 15051.4 |
Common Stock | 293.413 | 293.413 | 293.413 | 293.413 | 293.413 |
Additional Paid-In Capital | 3378.07 | 3371.13 | 3365.09 | 3372.8 | 3360.75 |
Retained Earnings (Accumulated Deficit) | 10759.2 | 10643.2 | 10851.4 | 10711.7 | 10478.5 |
Other Equity, Total | -424.13 | -779.544 | -682.02 | -388.468 | 918.768 |
Total Liabilities & Shareholders’ Equity | 35634.7 | 34960.1 | 35500.5 | 35754.1 | 38406.4 |
Total Common Shares Outstanding | 293.413 | 293.413 | 293.413 | 293.413 | 293.413 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 894.325 | 1219.03 | 1435.83 | 1438.5 | 2225.66 |
Cash From Operating Activities | 2167.38 | 2489.5 | 4233.16 | 2566.95 | 2061.91 |
Cash From Operating Activities | 1838.36 | 1623.68 | 1785.9 | 1593.16 | 724.847 |
Deferred Taxes | -41.471 | 67.259 | 111.104 | 64.266 | 89.171 |
Non-Cash Items | 126.649 | 232.342 | 215.137 | 304.705 | -824.73 |
Cash Taxes Paid | 334.615 | 345.052 | 301.663 | 387.719 | 358.386 |
Cash Interest Paid | 350.681 | 341.629 | 379.994 | 470.223 | 311.971 |
Changes in Working Capital | -650.487 | -652.807 | 685.184 | -833.68 | -153.034 |
Cash From Investing Activities | -734.725 | -1196.23 | -1334.94 | -3285.99 | -245.039 |
Capital Expenditures | -770.336 | -886.715 | -1085.23 | -1162.76 | -1142.38 |
Other Investing Cash Flow Items, Total | 35.611 | -309.513 | -249.709 | -2123.22 | 897.34 |
Cash From Financing Activities | -1617.36 | -1024.38 | -2664.03 | -466.633 | -681.736 |
Financing Cash Flow Items | -123.95 | -279.535 | -693.531 | 153.387 | -528.009 |
Total Cash Dividends Paid | -395.556 | -392.455 | -351.17 | -354.636 | -324.838 |
Issuance (Retirement) of Stock, Net | 20.153 | 6.511 | -353.335 | -583.932 | 10.183 |
Issuance (Retirement) of Debt, Net | -1118.01 | -358.903 | -1265.99 | 318.548 | 160.928 |
Foreign Exchange Effects | -23.162 | 131.228 | -160.371 | 47.76 | 32.387 |
Net Change in Cash | -207.868 | 400.116 | 73.816 | -1137.91 | 1167.52 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 133.853 | 894.325 | 700.743 | 417.811 | 211.806 |
Cash From Operating Activities | 142.835 | 2167.38 | 1567.72 | 910.11 | 158.697 |
Cash From Operating Activities | 437.814 | 1838.36 | 1343.69 | 841.707 | 418.957 |
Deferred Taxes | -22.373 | -41.471 | -60.08 | -63.14 | -9.295 |
Non-Cash Items | 29.157 | 126.649 | 103.348 | 193.575 | 54.974 |
Cash Taxes Paid | 33.575 | 334.615 | 233.758 | 197.797 | 44.301 |
Cash Interest Paid | 77.255 | 350.681 | 238.716 | 138.032 | 79.484 |
Changes in Working Capital | -435.616 | -650.487 | -519.981 | -479.843 | -517.745 |
Cash From Investing Activities | -163.277 | -734.725 | -509.78 | -408.988 | -211.316 |
Capital Expenditures | -146.326 | -723.988 | -534.505 | -395.112 | -198.313 |
Other Investing Cash Flow Items, Total | -16.951 | -10.737 | 24.725 | -13.876 | -13.003 |
Cash From Financing Activities | 2.014 | -1617.36 | -1497.44 | -994.912 | -266.641 |
Financing Cash Flow Items | 150.852 | -123.95 | -128.948 | 73.638 | 464.211 |
Issuance (Retirement) of Stock, Net | 0 | 20.153 | 20.151 | 20.145 | 0.792 |
Issuance (Retirement) of Debt, Net | -148.838 | -1118.01 | -993.091 | -693.139 | -731.644 |
Foreign Exchange Effects | -31.469 | -23.162 | 71.401 | 36.807 | 10.947 |
Net Change in Cash | -49.897 | -207.868 | -368.103 | -456.983 | -308.313 |
Total Cash Dividends Paid | -395.556 | -395.556 | -395.556 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Fresenius SE & Co KGaA | Corporation | 32.1663 | 94380382 | 0 | 2023-07-10 | LOW |
Pzena Investment Management, LLC | Investment Advisor/Hedge Fund | 5.2 | 15257499 | 0 | 2023-07-10 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.1 | 12030043 | -14667 | 2023-04-25 | LOW |
Harris Associates L.P. | Investment Advisor/Hedge Fund | 3.0475 | 8941673 | 156888 | 2023-09-06 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 3.0017 | 8807448 | -5315479 | 2023-01-03 | LOW |
Artisan Partners Limited Partnership | Investment Advisor | 2.9941 | 8785062 | 0 | 2023-01-02 | LOW |
Templeton Investment Counsel, L.L.C. | Investment Advisor/Hedge Fund | 2.1996 | 6453866 | -991203 | 2023-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0306 | 5957921 | 3674 | 2023-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.2147 | 3564186 | -379946 | 2022-12-31 | LOW |
Fidelity International | Investment Advisor | 0.9745 | 2859434 | 3183 | 2023-08-31 | LOW |
Lazard Asset Management, L.L.C. | Investment Advisor/Hedge Fund | 0.879 | 2579072 | -127568 | 2023-09-30 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.7656 | 2246374 | 1520 | 2023-09-30 | LOW |
BlackRock Asset Management Deutschland AG | Investment Advisor | 0.6937 | 2035291 | -9558 | 2023-09-30 | LOW |
Fiduciary Management, Inc. | Investment Advisor | 0.6536 | 1917700 | 433050 | 2023-06-30 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.6366 | 1867837 | 67354 | 2023-09-30 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.6276 | 1841411 | 2480 | 2023-09-30 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 0.5269 | 1545857 | 647740 | 2023-08-31 | LOW |
Lazard Fund Managers (Ireland) Limited | Investment Advisor | 0.4727 | 1387051 | -50000 | 2023-04-30 | |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4689 | 1375856 | 1130 | 2023-09-30 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.4304 | 1262837 | 95310 | 2023-09-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Fresenius Medical Care Company profile
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Fresenius Medical Care AG & Co. KGaA revenues decreased 1% to EUR17.62B. Net income decreased 17% to EUR969M. Revenues reflect Health Care Services decrease of 2% to EUR13.88B, Health Care Products remaining flat at EUR3.74B. Net income also reflects Income from equity method investees decrease of 3% to EUR92M (income). Dividend per share increased from EUR1.34 to EUR1.35.
Equity composition
1/2006, 1-for-1 Complex capital change(Factor: 1). 3/2006, Company name changed from Fresenius Medical Care AG. 06/2007, 3-for-1 stock split.
Industry: | Healthcare Facilities & Services (NEC) |
Else-Kröner-Straße 1
BAD HOMBURG VOR DER HOHE
HESSEN 61352
DE
Income Statement
- Annual
- Quarterly
News
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?
UK banks will be in the spotlight in the week ahead as the European earnings season continues
16:38, 16 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com